At the time of this publication, a phase I trial (NCT04995003) is recruiting patients to evaluate the safety of HER2 targeted CAR T cell therapy in combination with an ICI (pembrolizumab or nivolumab), in patients with HER2+ sarcoma. Here, ERBB2 is linked to sarcoma.